## Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 4

### CATALYST PHARMACEUTICAL PARTNERS, INC.

Form 4

February 14, 2012

February 14,	2012									
FORM	14 UNITED STATE	OMB	PPROVAL 3235-0287							
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).  Washington, D.C. 20549  Number:  Expires:  STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES  SECURITIES  SECURITIES  Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type I	Responses)									
	address of Reporting Person ** Z PATRICK J	2. Issuer Name <b>and</b> Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer				
			CATALYST PHARMACEUTICAL PARTNERS, INC. [CPRX]				(Check all applicable)			
	(First) (Middle)  MBRA CIRCLE, SUITE	3. Date of Earliest Tr. (Month/Day/Year) 02/14/2012	ansaction			_X_ Director _X_ Officer (give below)	_X10% titleOther below) ident and CEO	6 Owner or (specify		
1500	(0)									
CORAL GA	(Street) ABLES, FL 33134	4. If Amendment, Da Filed(Month/Day/Year)	_			6. Individual or Jo Applicable Line) _X_ Form filed by C Form filed by M	One Reporting Pe	rson		
(City)	(State) (Zip)					Person				
					_	uired, Disposed of				
1.Title of Security (Instr. 3)	any	ion Date, if Transaction Code /Day/Year) (Instr. 8)	4. Securition(A) or Dis (Instr. 3, 4)	posed	of (D)	•	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock, par value \$0.001 per share	02/14/2012	P P	1,600	A		3,179,147	D			
Common Stock, par value \$0.001 per share	02/14/2012	P	23,400	A	\$ 1.15	3,202,547	D			

· (1)

145,922 I

#### Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 4

Common Stock, par value \$0.001 per share

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed			7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secun Bene Owne Follo Repo Trans	
					of (D) (Instr. 3,						(Instr
				Code W	4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
MCENANY PATRICK J 355 ALHAMBRA CIRCLE, SUITE 1500 CORAL GABLES FL 33134	X	X	President and CEO				

## **Signatures**

/s/ Patrick J. 02/14/2012 McEnany \*\*Signature of Date Reporting Person

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares are owned by the Reporting Person's spouse

Reporting Owners 2

### Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.